



Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

| | |
|-------------------------------|--|
| Journal: | <i>British Journal of Clinical Pharmacology</i> |
| Manuscript ID | MP-00620-15.R1 |
| Manuscript Type: | Clinical trials |
| Date Submitted by the Author: | 18-Nov-2015 |
| Complete List of Authors: | Lazaar, Aili; GlaxoSmithKline, Yang, Lucy; Cambridge University, Clinical Pharmacology Unit Boardley, Rebecca Goyal, Navin; GlaxoSmithKline, Clinical Pharmacology, Modeling and Simulation Robertson, Jonathan Baldwin, Sandra Newby, David; Royal Infirmary, Edinburgh, Department of Cardiology Wilkinson, Ian; Addenbrooke's Hospital, Clinical Pharmacology Unit Tal-Singer, Ruth Mayer, Ruth Cheriyan, Joseph |
| Key Words: | epoxide hydrolase, clinical trial, COPD, pharmacokinetics, smokers |
| Abstract: | <p>Aims: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and are metabolised by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a potent and selective sEH inhibitor that was tested in two Phase I studies.</p> <p>Methods: Single escalating doses of GSK2256294 2-20 mg or placebo were administered in a randomized crossover design to healthy male subjects or obese smokers; once daily doses of 6 or 18 mg or placebo were administered for 14 days to obese smokers. Data were collected on safety, pharmacokinetics, sEH enzyme inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were also administered to healthy younger males or healthy elderly males and females with and without food. Data on safety, pharmacokinetics and biliary metabolites were collected.</p> <p>Results: GSK2256294 was well-tolerated with no serious adverse events (AEs) attributable to the drug. The most frequent AEs were headache and contact dermatitis. Plasma concentrations of GSK2256294 increased with single doses, with a half-life averaging 25-43 hours. There was no significant effect of age, food or gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 hours. There were no significant changes in serum VEGF or plasma fibrinogen.</p> <p>Conclusions: GSK2256294 was well-tolerated and demonstrated sustained</p> |

| | |
|--|--|
| | inhibition of sEH enzyme activity. These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD. |
| | |

SCHOLARONE™
Manuscripts

1 **Pharmacokinetics, pharmacodynamics and adverse event**
2 **profile of GSK2256294, a novel soluble epoxide hydrolase**
3 **inhibitor**

4 **Aili L. Lazaar¹, Lucy Yang², Rebecca L. Boardley³, Navin S. Goyal¹, Jonathan**
5 **Robertson³, Sandra J. Baldwin³, David E. Newby⁵, Ian B. Wilkinson², Ruth**
6 **Tal-Singer¹, Ruth J. Mayer¹, Joseph Cheriyan^{2,3,4}**

7 1. GSK R&D, King of Prussia, PA, USA

8 2. Experimental Medicine & Immunotherapeutics, Department of Medicine, University of
9 Cambridge, and Cambridge Clinical Trials Unit, Cambridge, UK

10 3. GSK R&D, Stevenage, Cambridge and Ware, UK

11 4. Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK

12 5. University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

13

14 **Author contact:**

15 Aili L. Lazaar, MD

16 GSK R&D

17 709 Swedeland Road, UW2351

18 King of Prussia, PA 19406, USA

19 ailli.lazaar@gsk.com

20

21

22 **Abstract**

23 **Aims:** Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and
24 are metabolised by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a
25 potent and selective sEH inhibitor that was tested in two Phase I studies.

26 **Methods:** Single escalating doses of GSK2256294 2-20 mg or placebo were
27 administered in a randomized crossover design to healthy male subjects or obese
28 smokers; once daily doses of 6 or 18 mg or placebo were administered for 14 days to
29 obese smokers. Data were collected on safety, pharmacokinetics, sEH enzyme
30 inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were also
31 administered to healthy younger males or healthy elderly males and females with
32 and without food. Data on safety, pharmacokinetics and biliary metabolites were
33 collected.

34 **Results:** GSK2256294 was well-tolerated with no serious adverse events (AEs)
35 attributable to the drug. The most frequent AEs were headache and contact
36 dermatitis. Plasma concentrations of GSK2256294 increased with single doses, with
37 a half-life averaging 25-43 hours. There was no significant effect of age, food or
38 gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-
39 dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8,
40 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 hours.
41 There were no significant changes in serum VEGF or plasma fibrinogen.

42 **Conclusions:** GSK2256294 was well-tolerated and demonstrated sustained
43 inhibition of sEH enzyme activity. These data support further investigation in patients
44 with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound
45 healing or COPD.

46

47 **What is known about this subject?**

- 48 • Soluble epoxide hydrolase (sEH) is a critical enzyme in the metabolism of
49 epoxyeicosatrienoic acids (EETs).

50

- 51 • EETs released from the endothelium exhibit anti-inflammatory effects,
52 regulate vascular tone and may have a cytoprotective role

53

- 54 • GSK2256294 is a potent and selective, orally-available sEH inhibitor

55

56 **What this study adds**

57 GSK2256294 is a well-tolerated and highly effective oral sEH inhibitor irrespective of
58 age, gender or food administration.

59 Introduction

60 Epoxyeicosatrienoic acids (EETs) are one of many vasoactive factors released by
61 the vascular endothelium, including nitric oxide (NO), prostacyclin, and endothelium
62 derived hyperpolarizing factors. EETs are formed by the oxidation of arachidonic acid
63 by cytochrome P450 enzymes. Soluble epoxide hydrolase (sEH, an *EPHX2* gene
64 product) is a critical enzyme in the metabolism of EETs to their corresponding much
65 less active or less available dihydroxyeicosatrienoic acids (DHETs) [1,2]. In addition,
66 *EPHX2* contains a phosphatase domain of unknown function. EETs have
67 demonstrated a wide range of activities including protection of endothelial cell
68 survival and function in both coronary and pulmonary derived cells, as well as anti-
69 inflammatory and pro-resolving functions and protection of organs from damage [3–
70 5]. The mechanism of action of EETs is complex, and may include changes in
71 potassium channel open states, as well as engagement of as yet unidentified
72 receptors or action through peroxisome proliferator-activated receptors [3].

73 Preclinical data with sEH inhibitors provide evidence for a number of potentially
74 beneficial cardioprotective effects [6–10]. Exogenous EETs and sEH inhibitors are
75 also efficacious in a wide variety of animal models of pulmonary disease such as
76 smoke-induced airway inflammation and airspace enlargement, allergen-induced
77 airway inflammation, bleomycin-induced pulmonary fibrosis and toxin-induced lung
78 injury [11–16]. High levels of sEH activity inversely correlate with low concentrations
79 of the pro-resolving lipoxin A4 in sputum supernatants of patients with severe asthma
80 [17]. It is proposed that the inhibition of sEH will increase the cellular concentration
81 of EETs and thus increase their positive cellular effects.

82 Clinical studies with sEH inhibitors are limited. The selective sEH inhibitor AR9281
83 (Arete Pharmaceuticals) was shown to improve endothelial function in animal models
84 [18] and demonstrated inhibition of enzyme activity and a modest decrease in

85 dihydroxy lipids in a clinical study in healthy subjects [19]. A Phase 2 trial to assess
86 effects on blood pressure and glucose metabolism in patients with moderate
87 hypertension and impaired glucose tolerance was terminated (NCT00847899).
88 GSK2256294 is a potent, tight-binding but reversible inhibitor of sEH. It is specific for
89 the hydrolase domain of *EPHX2* and is inactive against the phosphatase domain and
90 has been shown to attenuate cigarette smoke-induced lung inflammation in animal
91 models [20]. We report data from two clinical trials designed to test the safety,
92 pharmacokinetics, and pharmacodynamics of GSK2256294 in healthy subjects.

93 **Methods**94 **Clinical Study design**

95 Study 1, First-time-in-human (FTIH, GSK protocol SEH114068, ClinicalTrials.gov
96 identifier NCT01762774). The FTIH study was a single-center, randomized, double-
97 blind, placebo-controlled design comprising four cohorts. Study 1 recruited healthy
98 male non-smokers between 18-65 years of age with body mass index (BMI) 19-
99 25kg/m² for Cohort 1, and moderately overweight smokers (defined as ≥ 10
100 cigarettes/day for at least 1 year prior to the screening visit) with BMI 26 – 35kg/m²
101 for Cohorts 2-4. Subjects with abnormal liver function, who were on statins, or who
102 had hypertension or other significant cardiac, pulmonary, metabolic, renal, or
103 gastrointestinal conditions, were excluded.

104 Single escalating doses of GSK2256294 (2, 6, 10, 12, and 20mg) or placebo were
105 administered in a randomised crossover design to Cohorts 1 and 2. Single dosing
106 subjects followed a 4-period dosing schedule with placebo insertion, such that all
107 subjects received placebo and three doses of the active drug randomly over the
108 course of the study. Subjects were assigned to the treatment regimens in
109 accordance with a randomisation schedule that included 4 sequences with 3 subjects
110 assigned to each sequence.

111 The emerging pharmacokinetic (PK) and pharmacodynamic (PD) data from Cohorts
112 1 and 2 were modelled with a population exposure-response analysis approach to
113 select appropriate doses for repeat dosing cohorts. Two cohorts of overweight
114 smokers were subsequently recruited for repeat dosing, with one cohort randomised
115 to receive either 6mg or placebo (Cohort 3), and another 18 mg or placebo (Cohort
116 4). Fifteen subjects were planned for each cohort with 12 randomised to the active
117 arm and 3 to placebo. Data were collected on safety, PK, sEH enzyme inhibition and
118 blood biomarkers. An experimental medicine study in Cohorts 3 and 4, to provide

119 early proof of mechanism of the potential biological effects of sEH inhibition on
120 endothelial function using measurements of forearm blood flow, was also included,
121 but reported separately [21]. The trial received favourable ethical opinion from the
122 London Bloomsbury Ethics Committee (12/LO/1832) as well as regulatory approval
123 by the MHRA.

124 Study 2, Food effect (GSK protocol SEH117023, ClinicalTrials.gov identifier
125 NCT02006537). The food effect study was open label and performed at a single
126 center. Subjects included healthy males between 18-45 years of age recruited for
127 Cohort 1, and healthy male and females (of non-child bearing potential) aged ≥ 60
128 years of age recruited for Cohort 2.

129 Subjects in Cohort 1 received a single dose of GSK2256294 10mg, and underwent
130 non-invasive bile sampling with the Entero-Test® device, as previously described
131 [22]. Subjects in Cohort 2 were randomized to receive two single doses of
132 GSK2256294 10 mg in both the fed and fasted state. This trial was reviewed and
133 approved by the Aspire Institutional Review Board (Santee, CA, USA).

134 Both studies complied with the Declaration of Helsinki 2008 and ICH Good Clinical
135 Practice guidelines, and full written informed consent was obtained from all
136 participants before the performance of any study-specific procedures. A complete list
137 of inclusion and exclusion criteria is available on clinicaltrials.gov.

138 **Safety**

139 Safety assessments were monitored using adverse event (AE) reporting, clinical
140 laboratory tests, vital signs, ECGs, and physical examinations. In the single dose
141 escalation phase of Study 1, 25-hour continuous Holter and electrocardiographic
142 monitoring were performed from 1hr pre-dose to 24 hours post-dose.

143 The addition of EETs and/or inhibition of sEH have been linked in preclinical studies
144 to two important activities that pose potential clinical risks. The first set of studies
145 concerns the role of EETs and sEH in VEGF signaling and expression [23,24]; for
146 this reason, we measured VEGF concentrations in the repeat dose cohorts of Study
147 1 (described below). The second set of studies concerns control of acute pulmonary
148 vasoconstriction and pulmonary hypertension. Mice in which the sEH gene has been
149 deleted develop pulmonary hypertension in response to chronic hypoxia, but sEH
150 inhibition in wild-type mice does not recapitulate the knockout [25]. At this time, a
151 role of the *EPHX2* gene in development of pulmonary hypertension is focused on the
152 phosphatase domain, which is unaffected by GSK2256294 [20]; nevertheless, we
153 measured pulmonary artery pressure using transthoracic echocardiography in the
154 repeat dose cohorts of Study 1.

155 **Measurement of GSK2256294**

156 GSK2256294 was extracted from 50 μ L of human plasma by protein precipitation
157 using acetonitrile containing an isotopically labelled internal standard ($[^2\text{H}_3^{13}\text{C}]$ -
158 GSK2256294) and extracts were analysed for GSK2256294 by HPLC-MS/MS using
159 a TurbolonSpray™ interface and multiple reaction monitoring. The assay was
160 validated over the range 0.6 to 250 ng/mL of GSK2256294, with calibration
161 correlation coefficients of >0.996 , obtained using $1/(x^2)$ weighted linear regression.
162 The assay precision (%CV) was $\leq 12.9\%$ for within-run and $\leq 4.7\%$ between-runs, with
163 an accuracy (%bias) between $-9.5\% \leq \text{bias} \leq 14.5\%$.

164 **Soluble Epoxide Hydrolase Activity Assay**

165 Blood samples were collected from subjects in Cohorts 1-4 (Study 1), immediately
166 mixed by inversion in NaF/Potassium oxalate containing tubes and stored at $2-8^\circ\text{C}$
167 for up to 12 hours (if not processed immediately). Whole blood samples were
168 assessed for both sEH activity and non-sEH mediated EET hydrolysis, by pre-

169 incubating for 20 minutes at room temperature with either 25 mM HEPES/10 μ M
170 CHAPS buffer (pH 7-7.6) either alone or with addition of a known potent sEH inhibitor
171 (final concentration 10 μ M GSK2188931), respectively. The reactions were initiated
172 by the addition of 14,15-EET-deuterated (d11) substrate in HEPES/CHAPS buffer
173 (0.45 μ M final concentration) and incubated for 30 minutes at room temperature. The
174 enzymatic reaction was terminated by the addition of zinc sulfate (3.3 mM final
175 concentration) and subsequently diluted with an equal volume of distilled water
176 (~300 μ L) prior to storage at ca. -70°C. Samples were analysed for the conversion of
177 14,15-EET-d11 to 14,15-DHET-d11 by LC/MS/MS, using an assay that was validated
178 over the range 0.5 to 500 ng/mL for 14,15-EET-d11 and 0.1 to 100 ng/mL for 14,15-
179 DHET-d11, with calibration correlation coefficients obtained using $1/(x^2)$ weighted
180 linear regression of >0.996 and 0.997, respectively. The assay precision (%CV) was
181 $\leq 17.5\%$ (14,15-EET-d11) and $\leq 13.3\%$ (14,15-DHET-d11) for within-run and $\leq 4.6\%$
182 (14,15-EET-d11) and $\leq 13.7\%$ (14,15-DHET-d11) between-runs, with an accuracy
183 (%bias) between $-9.2\% \leq \text{bias} \leq 5.7\%$ (14, 15 EET) and $-5.5\% \leq \text{bias} \leq 22.9\%$ (14, 15
184 DHET). The sEH activity was evaluated by the formation of 14,15-DHET-d11,
185 corrected for non-sEH mediated hydrolysis and subsequently the % inhibition of sEH
186 activity following GSK2256294 dose escalation was defined.

187 **Blood biomarkers**

188 VEGF was measured using a validated ELISA (performed by Quest Diagnostics,
189 Valencia, CA). Plasma fibrinogen was measured using the modified Clauss method.
190 Detailed methods for the analysis of Leukotoxin/Leukotoxin-diol (LT/LTD) assays are
191 included in the Supplemental material [26].

192 **Analysis and Statistical methods**

193 These studies focused primarily on the safety, tolerability, and pharmacokinetics (PK)
194 of GSK2256294, and no formal hypotheses around the pharmacodynamic
195 assessments were tested.

196 Plasma concentration-time data were analysed by non-compartmental methods with
197 WinNonlin 6.3 and calculations were based on the actual sampling times recorded
198 during the study. Actual elapsed times from dosing were used to estimate all
199 individual plasma PK parameters for evaluable subjects. Based on available data,
200 various PK parameters were estimated following GSK2256294 dose administration in
201 single dose and repeat dose, including maximum observed plasma concentration
202 (C_{max}), time to C_{max} (t_{max}), the apparent terminal elimination half-life ($t_{1/2}$), and
203 the area under the plasma concentration-time curve (AUC). Descriptive statistics (n,
204 arithmetic mean, standard deviation, 90% CI, minimum, median and maximum) were
205 calculated for all PK parameters by treatment. Dose proportionality was assessed by
206 using Power model and Analysis of Variance.

207 A preliminary interim analysis of the systemic concentrations of GSK2256294
208 (exposure) and the sEH enzyme inhibition (response) data was conducted to select a
209 starting dose for the repeat dose arm using a population modeling and simulation
210 approach.

211

212

213 **Results**214 **Safety**

215 Fifty-six male subjects aged 18-65 years inclusive were recruited to take part in
216 Study 1. Fourteen healthy male non-smokers were recruited into cohort 1, and 42
217 moderately overweight smokers were recruited into cohorts 2 - 4. Forty-eight
218 subjects completed the study as planned. Detailed subject disposition is shown in
219 Figure 1. In study 2, 8 subjects were randomized into Cohort 1 and 18 subjects were
220 randomized into Cohort 2. All subjects completed the study. Demographics for both
221 studies are shown in Table S1 of the online supplement.

222 Overall, GSK2256294 was well-tolerated with no serious adverse reactions attributed
223 to the drug. One serious adverse event of nephrolithiasis occurred in a subject who
224 received a single dose of 2 mg in Study 1; this subject had a previous history of
225 nephrolithiasis and the event was not considered to be drug-related, although the
226 subject was withdrawn from the study. One additional subject was withdrawn after a
227 vasovagal episode while a blood sample was being obtained, which was not felt to
228 be drug-related. No subjects were withdrawn for adverse events in the repeat dose
229 cohorts.

230 The most frequent adverse events in study 1 were headache and contact dermatitis
231 in the healthy subjects (Cohort 1), and headache and nasopharyngitis in the obese
232 smokers (cohorts 2-4)(Supplemental Tables S2-S4). The occurrence of AEs was
233 similar between the active and placebo groups, with the exception of contact
234 dermatitis at the site of ECG electrode placement, which occurred in 9 healthy
235 subjects receiving the active drug, and none in the placebo group. The majority of
236 AEs were mild-moderate in severity. In the single dose cohorts, five subjects were
237 noted to have a transient elevation of creatinine at the 12 hour time point after dosing
238 (1 on placebo, 2 each on GSK2256294 2mg or 6 mg). Contemporaneous Cystatin C

239 concentrations in these subjects were normal (data not shown) and creatinine
240 concentrations were within the normal range at the 24 hour time point. No changes
241 in creatinine were noted in the repeat dose cohorts. The subject with nephrolithiasis
242 was noted to have increased hepatic transaminases at the time of his hospitalization.
243 One additional subject had a transient increase in alanine aminotransferase noted
244 after a single dose of 10 mg GSK2256294; no clinically significant changes in
245 transaminases were seen in the repeat dose cohorts. Finally, there were no changes
246 in the pulmonary artery pressures of subjects who received 14 days repeat dosing of
247 GSK2256294 in Study 1.

248 There were 3 AEs in study 2 and none was reported in more than one person (Table
249 S5). No clinically significant differences in ECG or vital signs were noted in either
250 study.

251 **Pharmacokinetics and Metabolism**

252 GSK256294 was well absorbed with maximum systemic concentrations achieved
253 around 1-2 hours and with a dose proportional increase in systemic exposure from 6
254 mg to 20 mg. The observed half-life was 20-30 hours (Figure 2A). The exposure and
255 $t_{1/2}$ were slightly higher in obese smokers as compared to healthy volunteers (Table
256 1). With once daily repeat dosing, steady state was achieved within 6-8 days and
257 resulted in approximately 2 fold accumulation (Figure 2B).

258 The preliminary exposure data and enzyme inhibition data from the single dose
259 cohorts in FTIH were utilized to characterize the sEH enzyme inhibition and
260 determine an approximate clinical dose for the repeat dose cohorts. An indirect
261 response model was built to characterize the sustained enzyme inhibition following
262 single dose administration. A population kinetic-pharmacodynamic model (KPD)
263 model adequately characterized the observed sEH enzyme inhibition at different
264 dose levels. The doses rather than systemic drug concentrations provided a better fit

265 of the observed data and this the KPD approach was used [27]. Simulations were
266 performed with the KPD model to predict the probability of 90% or higher level of
267 enzyme inhibition after 2 weeks of once daily dosing at different dose levels. The 6
268 mg dose presented a very high probability of achieving >90% sEH enzyme inhibition
269 at once daily dosing for 2 weeks. Assuming a less than 2 fold accumulation, the 18
270 mg dose was then selected to help characterize the safety and tolerability of a high
271 dose of GSK2256294, while maintaining exposures within the stopping criteria based
272 on animal safety studies.

273 Data from Study 2 demonstrated no impact on systemic exposure of GSK2256294
274 due to age or gender. There was an approximately 22% increase 1.22 (90% CI 1.10,
275 1.34) in AUC when GSK2256294 was administered with FDA recommended meal as
276 compared to fasted state with no change in the C_{max}. This increase in exposure
277 when GSK2256294 is administered with food is clinically insignificant.

278

279 In Study 2, GSK2256294 and five metabolites were detected in the pooled human
280 duodenal bile samples by mass spectroscopy. Unchanged parent was the major
281 drug-related component, with metabolites being formed by oxidation with or without
282 subsequent glucuronidation (data not shown).

283

284 **sEH Enzyme inhibition**

285 . Following single doses of GSK2256294, there was a dose-dependent inhibition
286 from an average of 41.9% on 2 mg (95% CI -51.8, 77.7) to an average of 99.8% on
287 20 mg (95% CI 99.3, 100.0)(Figure 3A). The duration of inhibition was sustained for
288 up to 24 hours. Near maximal inhibition of sEH enzyme activity (98-99%) was
289 observed for both 6mg and 18 mg following 14 days repeated dosing (Figure 3B).
290 Repeat dose enzyme inhibition at 6 mg/day and 18 mg/day (Cohorts 3 and 4,

291 respectively) was consistent with the single dose inhibition at 6 hr (98-99 %) at both
292 doses, and this was maintained at 24h after repeat dosing.

293 A large number of the endogenous LT levels were non-quantifiable, as they were
294 below the limit of LC/MS/MS assay detection (LLQs of 250 pg/mL and 50 pg/mL for
295 LT and LTD, respectively). In addition, there were no meaningful changes in the
296 LT/LTD ratio between any of the three treatment arms compared to baseline at any
297 time point (data not shown).

298 **Blood biomarkers**

299 In the repeat dosing subjects in Study 1, there were no significant changes in VEGF
300 concentrations from baseline to day 15. The fold change from baseline in the placebo
301 group was 1.06 (95% CI: 0.73, 1.55), and 1.15 (95% CI: 0.85, 1.56), in the 6mg
302 group. There was a trend for a decrease in VEGF in subjects receiving 18mg of
303 GSK2256294 (ratio to baseline 0.77 (95% CI: 0.56, 1.05)).

304 Adjusted mean values of plasma fibrinogen were within the normal range and were
305 similar across all groups. The average difference at day 15 compared with placebo
306 was negligible. The fold change from baseline in subjects who received 6mg
307 GSK2256294 was 1.06 (95% CI: 0.82, 1.37), and 1.04 (95% CI: 0.81, 1.34) in those
308 who received 18mg GSK2256294.

309

310 **Discussion**

311 We report the first studies to assess the safety, pharmacokinetics and
312 pharmacodynamic effects of the sEH inhibitor GSK2256294, in healthy subjects and
313 otherwise healthy overweight smokers. Overweight smokers represent a population
314 with endothelial dysfunction manifested by reduced NO-mediated vasodilatation and
315 impaired fibrinolytic pathways; in this situation, up-regulation of EETs would be
316 expected to play a compensatory role. Preclinical studies of sEH inhibition in models
317 of metabolic syndrome support obesity as a factor regulating this pathway [8,28].
318 Finally, smoking has a synergistic effect with sEH polymorphisms coding for
319 enhanced sEH enzyme [29], though subjects were not genotyped in this study.

320 GSK2256294 was rapidly absorbed and demonstrated an approximately dose
321 proportional increase in exposure from 6 mg to 20 mg dose with a half life consistent
322 with once daily dosing. The majority of GSK2256294 was cleared within 72 hrs of
323 dosing, yet very low concentrations of parent compound were detectable in the
324 plasma for up to 3 weeks. While the mechanism for this is unknown, one potential
325 explanation may be that a small amount of GSK2256294 is distributed to a deep
326 compartment and was then eliminated slowly.

327 GSK2256294 was well tolerated following both single and repeat dosing, and the
328 majority of adverse events were classified as mild to moderate. Transient elevations
329 of creatinine were noted in the single dose cohorts of the FTIH study that were
330 considered possibly drug-related, and occurred primarily in subjects receiving
331 GSK2256294. These events were only noted at a single time point, occurred soon
332 after a meal and only at 2 and 6 mg but not higher doses, and did not re-occur with
333 subsequent dosing, nor were they associated with elevations in serum cystatin C or
334 urinalysis abnormalities. No changes in creatinine were observed in the repeat dose
335 cohorts. The etiology of these transient changes is unknown. One possibility which

336 may explain why this was only seen at lower doses, and not in repeat dosing, is the
337 fact that the 12 hour blood sampling point was only done in Cohorts 1 and 2, i.e.
338 immediately after the evening meal, and that the changes in creatinine were related
339 to dietary intake (a heavy protein meal eaten immediately prior to sampling) as
340 previously reported in the literature [30], although a formal dietary chart was not kept
341 for the trial.

342 In pre-clinical models, EETs increase the proliferation and survival of endothelial
343 cells [31] as well as induce angiogenesis [32,33]. The critical role for EETs in organ
344 regeneration and tissue repair may be dependent on this effect [34]. Using the same
345 experimental model, investigators also demonstrated that transgenic overexpression
346 of EETs or inhibition of sEH promoted tumor growth and metastasis [35]. In contrast,
347 dual inhibition of cyclo-oxygenase 2 and soluble epoxide hydrolase has
348 demonstrated synergistic anti-angiogenic and anti-cancer activity [36]. The
349 relevance of these models to humans is unknown, but suggests that the regulation of
350 sEH activity and tissue EETs in tumor growth is complex. In the FTIH study, serum
351 VEGF concentrations were not increased following 2 weeks of dosing with
352 GSK2256294, and actually trended lower in subjects who received the higher dose.
353 One might speculate that in presence of an sEH inhibitor, stabilization of EET levels
354 results in enhanced local utilization reducing concentrations of VEGF, although long
355 term studies are necessary to fully assess the potential effects.

356 More recent studies have suggested that under conditions of low VEGF signaling,
357 EETs may increase the response to VEGF [23,24], thus, offering a novel therapeutic
358 approach to target endothelial apoptosis and subsequent tissue loss, as has been
359 demonstrated in emphysema [37–41]. Our results demonstrate that sEH inhibition
360 with GSK2256294 is well tolerated, with rapid and sustained target inhibition. The
361 results from these studies provide a meaningful rationale for future studies with

362 GSK2256294, particularly in diseases characterized by endothelial dysfunction or
363 abnormal tissue repair, such as diabetes, wound healing or emphysema.

364

British Journal of Clinical Pharmacology

365 Acknowledgements

366 The authors would like to thank the study volunteers, Dr. Disala Fernando and the
367 staff at the GSK Clinical Unit Cambridge, Addenbrooke's Centre for Clinical
368 Investigation (UK) and at the Parexel Early Phase Clinical Unit (Baltimore, MD,
369 USA), and Wayne Wright (GSK) for sEH enzyme assay and leukotoxin biomarker
370 methodology development. LY is funded by a Wellcome Trust-GSK Translational
371 Medicine and Therapeutics (TMAT) Studentship and a Raymond and Beverley
372 Sackler Fellowship. IW is a British Heart Foundation Senior Clinical Fellow, and both
373 JC and IW are supported by the Cambridge NIHR Biomedical Research Centre.

374

375 Competing Interests

376

377 AL, JR, NG, RB, SB, RTS and RM are GSK employees and shareholders. JC is
378 employed by Cambridge University Hospitals NHS Foundation Trust and is obligated
379 to spend 50% of his time on GSK clinical trial research; however, he receives no
380 other benefits or compensation from GSK. DN has received consultancy fees from
381 GSK; IW has received educational grants from GSK. LY has no conflicts to declare.

382

383 Funding for the two studies (NCT01762774 and NCT02006537) was provided by
384 GSK. Partial funding for Study 1 was provided by the Innovate UK Stratified
385 Medicines programme (ERICA Consortium).

386

387 Contributions

388 AL, JR, NG, RB, RM, DN, IW and JC designed the clinical studies; SB developed the
389 assay methodology; all authors analyzed and/or interpreted the data; AL and LY
390 wrote the first draft; all authors reviewed and approved the manuscript.

391

392 **Figure Legends**393 **Figure 1:** Subject Disposition, Study 1

394

395

396 **Figure 2: Single and Repeat Dose Pharmacokinetics of GSK2256294.**

397 Concentration-time plots following single (A) and repeat (B) doses of GSK2256294.

398 Data are expressed as mean \pm SD. HV-healthy volunteer; OS-overweight smoker

399

400

401 **Figure 3: Dose-dependent inhibition of sEH enzyme activity.** Percent inhibition
402 of sEH enzyme activity following single (A) and repeat (B) dosing with GSK2256294.403 Data are expressed as mean \pm SD. HV-healthy volunteer; OS-overweight smoker

404

405

406 **References**

- 407 1. Morisseau C, Hammock BD. Impact of Soluble Epoxide Hydrolase and
408 Epoxyeicosanoids on Human Health. Annual Review of Pharmacology and
409 Toxicology. 2012. p. 37–58.
- 410 2. Zhang G, Kodani S, Hammock BD. Stabilized epoxygenated fatty acids
411 regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res.
412 2014;53(1):108–23.
- 413 3. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular
414 function. Am J Physiol Cell Physiol. 2007;292(3):C996–1012.
- 415 4. Bellien J, Joannides R, Richard V, Thuillez C. Modulation of cytochrome-
416 derived epoxyeicosatrienoic acids pathway: A promising pharmacological
417 approach to prevent endothelial dysfunction in cardiovascular diseases?
418 Pharmacol Ther. 2011;131(1):1–17.
- 419 5. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for
420 cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794–805.
- 421 6. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory
422 properties of cytochrome P450 epoxygenase-derived eicosanoids. Science.
423 1999;285(5431):1276–9.
- 424 7. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW,
425 Zeldin DC. Up-regulation of endothelial nitric-oxide synthase by endothelium-
426 derived hyperpolarizing factor involves mitogen-activated protein kinase and
427 protein kinase C signaling pathways. J Pharmacol Exp Ther.
428 2003;307(2):753–64.
- 429 8. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, Lee, C,
430 Zeldin DC, Schwartzman ML. CYP2J2 targeting to endothelial cells
431 attenuates adiposity and Vascular Dysfunction in Mice Fed a High-Fat Diet by
432 Reprogramming Adipocyte Phenotype. Hypertension. 2014;64(6):1352–61.
- 433 9. Dufлот T, Roche C, Lamoureux F, Guerrot D, Bellien J. Design and discovery
434 of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular
435 diseases. Expert Opin Drug Discov. 2014;9(3):229–43.
- 436 10. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and
437 cardioprotection: The road to translation. Journal of Molecular and Cellular
438 Cardiology. 2014. p. 199–208.
- 439 11. Zheng J, Plopper CG, Lakritz J, Storms DH, Hammock BD. Leukotoxin-diol: A
440 putative toxic mediator involved in acute respiratory distress syndrome. Am J
441 Respir Cell Mol Biol. 2001;25(4):434–8.
- 442 12. Yang J, Bratt J, Franzi L, Liu J-Y, Zhang G, Zeki A, Voge CF, Williams K,
443 Dong H, Lin Y, Hwang SH, Kenyon NJ, Hammock BD. Soluble Epoxide
444 Hydrolase Inhibitor Attenuates Inflammation and Airway
445 Hyperresponsiveness in Mice. Am J Respir Cell Mol Biol. 2015;52(1):46–55.

- 446 13. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock BD, Pinkerton,
447 Kent E.. Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic
448 obstructive pulmonary disease. *Am J Respir Cell Mol Biol*. 2012;46(5):614–22.
- 449 14. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD.
450 Attenuation of tobacco smoke-induced lung inflammation by treatment with a
451 soluble epoxide hydrolase inhibitor. *Proc Natl Acad Sci U S A*.
452 2005;102(6):2186–91.
- 453 15. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S,
454 Chalfant C, Conrad DH, Kepley CL. Epoxyeicosatrienoic acids are involved in
455 the C 70 fullerene derivative-induced control of allergic asthma. *J Allergy Clin
456 Immunol*. 2012;130(3).
- 457 16. Zhou Y, Sun G-Y, Liu T, Duan J-X, Zhou H-F, Lee KS, Hammock BD, Fang
458 X, Jiang J-X, Guan C-X. Soluble epoxide hydrolase inhibitor 1-
459 trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates
460 bleomycin-induced pulmonary fibrosis in mice. *Cell Tissue Res*. 2015;.
461 Available from: <http://link.springer.com/10.1007/s00441-015-2262-0>
- 462 17. Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, Douda DH,
463 Tabet Y, Khaddaj-Mallat R, Sirois M, Sirois C, Rizcallah E, Rousseau E,
464 Martin R, Sutherland ER, Castro M, Jarjour N, Israel E, Levy BD.. Lipoxin
465 Generation Is Related to Soluble Epoxide Hydrolase Activity in Severe
466 Asthma. *Am J Respir Crit Care Med* . 2014;190(8):886–97.
- 467 18. Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y,
468 Do, Zung N, Mehra U, Tran V. 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-
469 urea (AR9281) as a potent, selective, and orally available soluble epoxide
470 hydrolase inhibitor with efficacy in rodent models of hypertension and
471 dysglycemia. *Bioorganic Med Chem Lett*. 2011;21(3):983–8.
- 472 19. Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV,
473 Anandan SK, Gless R, Webb HK. Pharmacokinetics and Pharmacodynamics
474 of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-
475 Dose Studies in Healthy Human Subjects. *The Journal of Clinical
476 Pharmacology*. 2012. p. 319–28.
- 477 20. Podolin PL, Bolognese BJ, Foley JF, Long E, Peck B, Umbrecht S, Zhang X,
478 Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M,
479 Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP, Kurali
480 E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF. In vitro and in
481 vivo characterization of a novel soluble epoxide hydrolase inhibitor.
482 *Prostaglandins Other Lipid Mediat [Internet]*. 2013;104-105:25–31.
- 483 21. Lazaar AL, Yang L, Robertson J, Goyal N, Boardley R, Tal-Singer R,
484 Cheriyan J, Newby D, Wilkinson I, Mayer RJ. Safety and pharmacology of a
485 soluble epoxide hydrolase inhibitor. *European Respiratory Society*. 2015.
486 Available from: <http://erscongress.org/key4.html>
- 487 22. Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney
488 WJ. Assessment of potential drug interactions by characterization of human
489 drug metabolism pathways using non-invasive bile sampling. *Br J Clin
490 Pharmacol*. 2013;75(2):488–96.

- 491 23. Webler AC, Michaelis UR, Popp R, Barbosa-Sicard E, Murugan A, Falck JR,
492 Fisslthaler B, Fleming I. Epoxyeicosatrienoic acids are part of the VEGF-
493 activated signaling cascade leading to angiogenesis. *Am J Physiol Cell*
494 *Physiol.* 2008;295(5):C1292–301.
- 495 24. Yang S, Wei S, Pozzi A, Capdevila JH. The arachidonic acid epoxygenase is a
496 component of the signaling mechanisms responsible for VEGF-stimulated
497 angiogenesis. *Arch Biochem Biophys.* 2009;489(1-2):82–91.
- 498 25. Keserü B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD,
499 Weissmann N, Fisslthaler B, Fleming I. Hypoxia-induced pulmonary
500 hypertension: Comparison of soluble epoxide hydrolase deletion vs.
501 inhibition. *Cardiovasc Res.* 2010;85(1):232–40.
- 502 26. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock
503 BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. *Nat*
504 *Med.* 1997;3(5):562–6.
- 505 27. Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer J-L. A
506 semimechanistic and mechanistic population PK-PD model for biomarker
507 response to ibandronate, a new bisphosphonate for the treatment of
508 osteoporosis. *Br J Clin Pharmacol.* 2004;58(6):618–31.
- 509 28. Zhao X, Dey A, Romanko OP, Stepp DW, Wang M-H, Zhou Y, Jin L, Pollock
510 JS, Webb RC, Imig JD Decreased epoxygenase and increased epoxide
511 hydrolase expression in the mesenteric artery of obese Zucker rats. *Am J*
512 *Physiol Regul Integr Comp Physiol.* 2005;288(1):R188–96.
- 513 29. Wei Q, Doris PA, Pollizotto M V., Boerwinkle E, Jacobs DR, Siscovick DS,
514 Fornage M. Sequence variation in the soluble epoxide hydrolase gene and
515 subclinical coronary atherosclerosis: Interaction with cigarette smoking.
516 *Atherosclerosis.* 2007;190(1):26–34.
- 517 30. Jacobsen FK, Christensen CK, Mogensen CE, Andreasen F, Heilskov NS.
518 Postprandial serum creatinine increase in normal subjects after eating cooked
519 meat. *Proc Eur Dial Transplant Assoc.* 1979;16:506–12.
- 520 31. Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck
521 JR, Harder DR, Jacobs ER, Pratt PF. Emerging mechanisms for growth and
522 protection of the vasculature by cytochrome P450-derived products of
523 arachidonic acid and other eicosanoids. *Prostaglandins and Other Lipid*
524 *Mediators.* 2007. 1-4:19–29.
- 525 32. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila
526 JH. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-
527 EET) as potent in vivo angiogenic lipids. *J Biol Chem.* 2005;280(29):27138–
528 46.
- 529 33. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis.
530 *Prostaglandins and Other Lipid Mediators.* 2007. p. 60–7.
- 531 34. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML,
532 Lee CR, Benny O, Mudge DK, Butterfield CE, Mammoto A, Mammoto T,
533 Inceoglu B, Jenkins RL, Simpson MA, Akino T, Lih FB, Tomer KB, Ingber DE,

- 534 Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M,
535 Zeldin DC, Kieran MW. Epoxyeicosanoids promote organ and tissue
536 regeneration. *Proc Natl Acad Sci U S A*. 2013;110(33):13528–33.
- 537 35. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield
538 CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM,
539 Dudley AC, Greene ER, Vergilio J, Pietramaggiori G, Scherer-Pietramaggiori
540 SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA,
541 Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA,
542 Kieran MW, Zeldin DC. Epoxyeicosanoids stimulate multiorgan metastasis
543 and tumor dormancy escape in mice. *J Clin Invest*. 2012;122(1):178–91.
- 544 36. Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu
545 J-Y, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW,
546 Hammock BD. Dual inhibition of cyclooxygenase-2 and soluble epoxide
547 hydrolase synergistically suppresses primary tumor growth and metastasis.
548 *Proc Natl Acad Sci*. 2014;111(30):11127–32.
- 549 37. Janssen WJ, Yunt ZX, Muldrow A, Kearns MT, Kloepfer A, Barthel L, Bratton
550 DL, Bowler RP, Henson PM. Circulating hematopoietic progenitor cells are
551 decreased in COPD. *COPD*. 2014;11(3):277–89.
- 552 38. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema.
553 *Journal of Clinical Investigation*. 2008. p. 394–402.
- 554 39. Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, Zhang, Z I. Mesenchymal stem
555 cell transplantation increases expression of vascular endothelial growth factor
556 in papain-induced emphysematous lungs and inhibits apoptosis of lung cells.
557 *Cytotherapy*. 2010;12(5):605–14.
- 558 40. Tang K, Rossiter HB, Wagner PD, Breen EC. Lung-targeted VEGF inactivation
559 leads to an emphysema phenotype in mice. *J Appl Physiol*. 2004;97(4):1559–
560 66.
- 561 41. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth
562 PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and
563 emphysema. *J Clin Invest*. 2000;106(11):1311–9.
- 564

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

Aili L. Lazaar¹, Lucy Yang², Rebecca L. Boardley³, Navin S. Goyal¹, Jonathan Robertson³, Sandra J. Baldwin³, David E. Newby⁵, Ian B. Wilkinson², Ruth Tal-Singer¹, Ruth J. Mayer¹, Joseph Cheriyan^{2,3,4}

1. GSK R&D, King of Prussia, PA, USA
2. Experimental Medicine & Immunotherapeutics, Department of Medicine, University of Cambridge, and Cambridge Clinical Trials Unit, Cambridge, UK
3. GSK R&D, Stevenage, Cambridge and Ware, UK
4. Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
5. University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Author contact:

Aili L. Lazaar, MD
GSK R&D
709 Swedeland Road, UW2351
King of Prussia, PA 19406, USA
ailli.lazaar@gsk.com

Abstract

Aims: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and are metabolised by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a potent and selective sEH inhibitor that was tested in two Phase I studies.

Methods: Single escalating doses of GSK2256294 2-20 mg or placebo were administered in a randomized crossover design to healthy male subjects or obese smokers; once daily doses of 6 or 18 mg or placebo were also administered for 14 days to obese smokers. Data were collected on safety, pharmacokinetics, sEH enzyme inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were also administered to healthy younger males or healthy elderly males and females with and without food. Data on safety, pharmacokinetics and biliary metabolites were collected.

Results: GSK2256294 was well-tolerated with no serious adverse events (AEs) attributable to the drug. The most frequent AEs were headache and contact dermatitis. Plasma concentrations of GSK2256294 increased with single doses, with a half-life averaging 25-43 hours. There was no significant effect of age, food or gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 hours. There were no significant changes in serum VEGF or plasma fibrinogen.

Conclusions: GSK2256294 was well-tolerated and demonstrated sustained inhibition of sEH enzyme activity. These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD.

What is known about this subject?

- Soluble epoxide hydrolase (sEH) is a critical enzyme in the metabolism of epoxyeicosatrienoic acids (EETs).
- EETs released from the endothelium exhibit anti-inflammatory effects, regulate vascular tone and may have a cytoprotective role
- GSK2256294 is a potent and selective, orally-available sEH inhibitor

What this study adds

GSK2256294 is a well-tolerated and highly effective oral sEH inhibitor irrespective of age, gender or food administration.

Introduction

Epoxyeicosatrienoic acids (EETs) are one of many vasoactive factors released by the vascular endothelium, including nitric oxide (NO), prostacyclin, and endothelium derived hyperpolarizing factors. EETs are formed by the oxidation of arachidonic acid by cytochrome P450 enzymes. Soluble epoxide hydrolase (sEH, an *EPHX2* gene product) is a critical enzyme in the metabolism of EETs to their corresponding much less active or less available dihydroxyeicosatrienoic acids (DHETs) [1,2]. In addition, *EPHX2* contains a phosphatase domain of unknown function. EETs have demonstrated a wide range of activities including protection of endothelial cell survival and function in both coronary and pulmonary derived cells, as well as anti-inflammatory and pro-resolving functions and protection of organs from damage [3–5]. The mechanism of action of EETs is complex, and may include changes in potassium channel open states, as well as engagement of as yet unidentified receptors or action through peroxisome proliferator-activated receptors [3].

Preclinical data with sEH inhibitors provide evidence for a number of potentially beneficial cardioprotective effects [6–10]. Exogenous EETs and sEH inhibitors are also efficacious in a wide variety of animal models of pulmonary disease such as smoke-induced airway inflammation and airspace enlargement, allergen-induced airway inflammation, bleomycin-induced pulmonary fibrosis and toxin-induced lung injury [11–16]. High levels of sEH activity inversely correlate with low concentrations of the pro-resolving lipoxin A₄ in sputum supernatants of patients with severe asthma [17]. It is proposed that the inhibition of sEH will increase the cellular concentration of EETs and thus increase their positive cellular effects.

Clinical studies with sEH inhibitors are limited. The selective sEH inhibitor AR9281 (Arete Pharmaceuticals) was shown to improve endothelial function in animal models [18] and demonstrated inhibition of enzyme activity and a modest decrease in

dihydroxy lipids in a clinical study in healthy subjects [19]. A Phase 2 trial to assess effects on blood pressure and glucose metabolism in patients with moderate hypertension and impaired glucose tolerance was terminated (NCT00847899). GSK2256294 is a potent, tight-binding but reversible inhibitor of sEH. It is specific for the hydrolase domain of *EPHX2* and is inactive against the phosphatase domain and has been shown to attenuate cigarette smoke-induced lung inflammation in animal models [20]. We report data from two clinical trials designed to test the safety, pharmacokinetics, and pharmacodynamics of GSK2256294 in healthy subjects.

Methods

Clinical Study design

Study 1, First-time-in-human (FTIH, GSK protocol SEH114068, ClinicalTrials.gov identifier NCT01762774). The FTIH study was a single-center, randomized, double-blind, placebo-controlled design comprising four cohorts. Study 1 recruited healthy male non-smokers between 18-65 years of age with body mass index (BMI) 19-25kg/m² for Cohort 1, and moderately overweight smokers (defined as ≥ 10 cigarettes/day for at least 1 year prior to the screening visit) with BMI 26 – 35kg/m² for Cohorts 2-4. Subjects with abnormal liver function, who were on statins, or who had hypertension or other significant cardiac, pulmonary, metabolic, renal, or gastrointestinal conditions, were excluded.

Single escalating doses of GSK2256294 (2, 6, 10, 12, and 20mg) or placebo were administered in a randomised crossover design to Cohorts 1 and 2. Single dosing subjects followed a 4-period dosing schedule with placebo insertion, such that all subjects received placebo and three doses of the active drug randomly over the course of the study. Subjects were assigned to the treatment regimens in accordance with a randomisation schedule that included 4 sequences with 3 subjects assigned to each sequence.

The emerging pharmacokinetic (PK) and pharmacodynamic (PD) data from Cohorts 1 and 2 were modelled with a population exposure-response analysis approach to select appropriate doses for repeat dosing cohorts. Two cohorts of overweight smokers were subsequently recruited for repeat dosing, with one cohort randomised to receive either 6mg or placebo (Cohort 3), and another 18 mg or placebo (Cohort 4). Fifteen subjects were planned for each cohort with 12 randomised to the active arm and 3 to placebo. Data were collected on safety, PK, sEH enzyme inhibition and blood biomarkers. An experimental medicine study in Cohorts 3 and 4, to provide

early proof of mechanism of the potential biological effects of sEH inhibition on endothelial function using measurements of forearm blood flow, was also included, but reported separately [21]. The trial received favourable ethical opinion from the London Bloomsbury Ethics Committee (12/LO/1832) as well as regulatory approval by the MHRA.

Study 2, Food effect (GSK protocol SEH117023, ClinicalTrials.gov identifier NCT02006537). The food effect study was open label and performed at a single center. Subjects included healthy males between 18-45 years of age recruited for Cohort 1, and healthy male and females (of non-child bearing potential) aged ≥ 60 years of age recruited for Cohort 2.

Subjects in Cohort 1 received a single dose of GSK2256294 10mg, and underwent non-invasive bile sampling with the Entero-Test® device, as previously described [22]. Subjects in Cohort 2 were randomized to receive two single doses of GSK2256294 10 mg in both the fed and fasted state. This trial was reviewed and approved by the Aspire Institutional Review Board (Santee, CA, USA).

Both studies complied with the Declaration of Helsinki 2008 and ICH Good Clinical Practice guidelines, and full written informed consent was obtained from all participants before the performance of any study-specific procedures. A complete list of inclusion and exclusion criteria is available on clinicaltrials.gov.

Safety

Safety assessments were monitored using adverse event (AE) reporting, clinical laboratory tests, vital signs, ECGs, and physical examinations. In the single dose escalation phase of Study 1, 25-hour continuous Holter and electrocardiographic monitoring were performed from 1hr pre-dose to 24 hours post-dose.

The addition of EETs and/or inhibition of sEH have been linked in preclinical studies to two important activities that pose potential clinical risks. The first set of studies concerns the role of EETs and sEH in VEGF signaling and expression [23,24]; for this reason, we measured VEGF concentrations in the repeat dose cohorts of Study 1 (described below). The second set of studies concerns control of acute pulmonary vasoconstriction and pulmonary hypertension. Mice in which the sEH gene has been deleted develop pulmonary hypertension in response to chronic hypoxia, but sEH inhibition in wild-type mice does not recapitulate the knockout [25]. At this time, a role of the *EPHX2* gene in development of pulmonary hypertension is focused on the phosphatase domain, which is unaffected by GSK2256294 [20]; nevertheless, we measured pulmonary artery pressure using transthoracic echocardiography in the repeat dose cohorts of Study 1.

Measurement of GSK2256294

GSK2256294 was extracted from 50 μ L of human plasma by protein precipitation using acetonitrile containing an isotopically labelled internal standard ($[^2\text{H}_3,^{13}\text{C}]$ -GSK2256294) and extracts were analysed for GSK2256294 by HPLC-MS/MS using a TurboIonSpray™ interface and multiple reaction monitoring. The assay was validated over the range 0.6 to 250 ng/mL of GSK2256294, with calibration correlation coefficients of >0.996 , obtained using $1/(x^2)$ weighted linear regression. The assay precision (%CV) was $\leq 12.9\%$ for within-run and $\leq 4.7\%$ between-runs, with an accuracy (%bias) between $-9.5\% \leq \text{bias} \leq 14.5\%$.

Soluble Epoxide Hydrolase Activity Assay

Blood samples were collected from subjects in Cohorts 1-4 (Study 1), immediately mixed by inversion in NaF/Potassium oxalate containing tubes and stored at $2-8^\circ\text{C}$ for up to 12 hours (if not processed immediately). Whole blood samples were assessed for both sEH activity and non-sEH mediated EET hydrolysis, by pre-

incubating for 20 minutes at room temperature with either 25 mM HEPES/10 μ M CHAPS buffer (pH 7-7.6) either alone or with addition of a known potent sEH inhibitor (final concentration 10 μ M GSK2188931), respectively. The reactions were initiated by the addition of 14,15-EET-deuterated (d11) substrate in HEPES/CHAPS buffer (0.45 μ M final concentration) and incubated for 30 minutes at room temperature. The enzymatic reaction was terminated by the addition of zinc sulfate (3.3 mM final concentration) and subsequently diluted with an equal volume of distilled water (~300 μ L) prior to storage at ca. -70°C. Samples were analysed for the conversion of 14,15-EET-d11 to 14,15-DHET-d11 by LC/MS/MS, using an assay that was validated over the range 0.5 to 500 ng/mL for 14,15-EET-d11 and 0.1 to 100 ng/mL for 14,15-DHET-d11, with calibration correlation coefficients obtained using $1/(x^2)$ weighted linear regression of >0.996 and 0.997, respectively. The assay precision (%CV) was \leq 17.5% (14,15-EET-d11) and \leq 13.3% (14,15-DHET-d11) for within-run and \leq 4.6% (14,15-EET-d11) and \leq 13.7% (14,15-DHET-d11) between-runs, with an accuracy (%bias) between $-9.2\% \leq$ bias \leq 5.7% (14, 15 EET) and $-5.5\% \leq$ bias \leq 22.9% (14, 15 DHET). The sEH activity was evaluated by the formation of 14,15-DHET-d11, corrected for non-sEH mediated hydrolysis and subsequently the % inhibition of sEH activity following GSK2256294 dose escalation was defined.

Blood biomarkers

VEGF was measured using a validated ELISA (performed by Quest Diagnostics, Valencia, CA). Plasma fibrinogen was measured using the modified Clauss method. Detailed methods for the analysis of Leukotoxin/Leukotoxin-diol (LT/LTD) assays are included in the Supplemental material [26].

Analysis and Statistical methods

These studies focused primarily on the safety, tolerability, and pharmacokinetics (PK) of GSK2256294, and no formal hypotheses around the pharmacodynamic assessments were tested.

Plasma concentration-time data were analysed by non-compartmental methods with WinNonlin 6.3 and calculations were based on the actual sampling times recorded during the study. Actual elapsed times from dosing were used to estimate all individual plasma PK parameters for evaluable subjects. Based on available data, various PK parameters were estimated following GSK2256294 dose administration in single dose and repeat dose, including maximum observed plasma concentration (C_{max}), time to C_{max} (t_{max}), the apparent terminal elimination half-life ($t_{1/2}$), and the area under the plasma concentration-time curve (AUC). Descriptive statistics (n, arithmetic mean, standard deviation, 90% CI, minimum, median and maximum) were calculated for all PK parameters by treatment. Dose proportionality was assessed by using Power model and Analysis of Variance.

A preliminary interim analysis of the systemic concentrations of GSK2256294 (exposure) and the sEH enzyme inhibition (response) data was conducted to select a starting dose for the repeat dose arm using a population modeling and simulation approach.

Results

Safety

Fifty-six male subjects aged 18-65 years inclusive were recruited to take part in Study 1. Fourteen healthy male non-smokers were recruited into cohort 1, and 42 moderately overweight smokers were recruited into cohorts 2 - 4. Forty-eight subjects completed the study as planned. Detailed subject disposition is shown in Figure 1. In study 2, 8 subjects were randomized into Cohort 1 and 18 subjects were randomized into Cohort 2. All subjects completed the study. Demographics for both studies are shown in Table S1 of the online supplement.

Overall, GSK2256294 was well-tolerated with no serious adverse reactions attributed to the drug. One serious adverse event of nephrolithiasis occurred in a subject who received a single dose of 2 mg in Study 1; this subject had a previous history of nephrolithiasis and the event was not considered to be drug-related, although the subject was withdrawn from the study. One additional subject was withdrawn after a vasovagal episode while a blood sample was being obtained, which was not felt to be drug-related. No subjects were withdrawn for adverse events in the repeat dose cohorts.

The most frequent adverse events in study 1 were headache and contact dermatitis in the healthy subjects (Cohort 1), and headache and nasopharyngitis in the obese smokers (cohorts 2-4)(Supplemental Tables S2-S4). The occurrence of AEs was similar between the active and placebo groups, with the exception of contact dermatitis at the site of ECG electrode placement, which occurred in 9 healthy subjects receiving the active drug, and none in the placebo group. The majority of AEs were mild-moderate in severity. In the single dose cohorts, five subjects were noted to have a transient elevation of creatinine at the 12 hour time point after dosing (1 on placebo, 2 each on GSK2256294 2mg or 6 mg). Contemporaneous Cystatin C

concentrations in these subjects were normal (data not shown) and creatinine concentrations were within the normal range at the 24 hour time point. No changes in creatinine were noted in the repeat dose cohorts. The subject with nephrolithiasis was noted to have increased hepatic transaminases at the time of his hospitalization. One additional subject had a transient increase in alanine aminotransferase noted after a single dose of 10 mg GSK2256294; no clinically significant changes in transaminases were seen in the repeat dose cohorts. Finally, there were no changes in the pulmonary artery pressures of subjects who received 14 days repeat dosing of GSK2256294 in Study 1.

There were 3 AEs in study 2 and none was reported in more than one person (Table S5). No clinically significant differences in ECG or vital signs were noted in either study.

Pharmacokinetics and Metabolism

GSK256294 was well absorbed with maximum systemic concentrations achieved around 1-2 hours and with a dose proportional increase in systemic exposure from 6 mg to 20 mg. The observed half-life was 20-30 hours (Figure 2A). The exposure and $t_{1/2}$ were slightly higher in obese smokers as compared to healthy volunteers (Table 1). With once daily repeat dosing, steady state was achieved within 6-8 days and resulted in approximately 2 fold accumulation (Figure 2B).

The preliminary exposure data and enzyme inhibition data from the single dose cohorts in FTIH were utilized to characterize the sEH enzyme inhibition and determine an approximate clinical dose for the repeat dose cohorts. An indirect response model was built to characterize the sustained enzyme inhibition following single dose administration. A population kinetic-pharmacodynamic model (KPD) model adequately characterized the observed sEH enzyme inhibition at different dose levels. The doses rather than systemic drug concentrations provided a better fit

of the observed data and this the KPD approach was used [27]. Simulations were performed with the KPD model to predict the probability of 90% or higher level of enzyme inhibition after 2 weeks of once daily dosing at different dose levels. The 6 mg dose presented a very high probability of achieving >90% sEH enzyme inhibition at once daily dosing for 2 weeks. Assuming a less than 2 fold accumulation, the 18 mg dose was then selected to help characterize the safety and tolerability of a high dose of GSK2256294, while maintaining exposures within the stopping criteria based on animal safety studies.

Data from Study 2 demonstrated no impact on systemic exposure of GSK2256294 due to age or gender. There was an approximately 22% increase 1.22 (90% CI 1.10, 1.34) in AUC when GSK2256294 was administered with FDA recommended meal as compared to fasted state with no change in the C_{max}. This increase in exposure when GSK2256294 is administered with food is clinically insignificant.

In Study 2, GSK2256294 and five metabolites were detected in the pooled human duodenal bile samples by mass spectroscopy. Unchanged parent was the major drug-related component, with metabolites being formed by oxidation with or without subsequent glucuronidation (data not shown).

sEH Enzyme inhibition

. Following single doses of GSK2256294, there was a dose-dependent inhibition from an average of 41.9% on 2 mg (95% CI -51.8, 77.7) to an average of 99.8% on 20 mg (95% CI 99.3, 100.0)(Figure 3A). The duration of inhibition was sustained for up to 24 hours. Near maximal inhibition of sEH enzyme activity (98-99%) was observed for both 6mg and 18 mg following 14 days repeated dosing (Figure 3B). Repeat dose enzyme inhibition at 6 mg/day and 18 mg/day (Cohorts 3 and 4,

respectively) was consistent with the single dose inhibition at 6 hr (98-99 %) at both doses, and this was maintained at 24h after repeat dosing.

A large number of the endogenous LT levels were non-quantifiable, as they were below the limit of LC/MS/MS assay detection (LLQs of 250 pg/mL and 50 pg/mL for LT and LTD, respectively). In addition, there were no meaningful changes in the LT/LTD ratio between any of the three treatment arms compared to baseline at any time point (data not shown).

Blood biomarkers

In the repeat dosing subjects in Study 1, there were no significant changes in VEGF concentrations from baseline to day 15. The fold change from baseline in the placebo group was 1.06 (95% CI: 0.73, 1.55), and 1.15 (95% CI: 0.85, 1.56), in the 6mg group. There was a trend for a decrease in VEGF in subjects receiving 18mg of GSK2256294 (ratio to baseline 0.77 (95% CI: 0.56, 1.05)).

Adjusted mean values of plasma fibrinogen were within the normal range and were similar across all groups. The average difference at day 15 compared with placebo was negligible. The fold change from baseline in subjects who received 6mg GSK2256294 was 1.06 (95% CI: 0.82, 1.37), and 1.04 (95% CI: 0.81, 1.34) in those who received 18mg GSK2256294.

Discussion

We report the first studies to assess the safety, pharmacokinetics and pharmacodynamic effects of the sEH inhibitor GSK2256294, in healthy subjects and otherwise healthy overweight smokers. Overweight smokers represent a population with endothelial dysfunction manifested by reduced NO-mediated vasodilatation and impaired fibrinolytic pathways; in this situation, up-regulation of EETs would be expected to play a compensatory role. Preclinical studies of sEH inhibition in models of metabolic syndrome support obesity as a factor regulating this pathway [8,28]. Finally, smoking has a synergistic effect with sEH polymorphisms coding for enhanced sEH enzyme [29], though subjects were not genotyped in this study.

GSK2256294 was rapidly absorbed and demonstrated an approximately dose proportional increase in exposure from 6 mg to 20 mg dose with a half life consistent with once daily dosing. The majority of GSK2256294 was cleared within 72 hrs of dosing, yet very low concentrations of parent compound were detectable in the plasma for up to 3 weeks. While the mechanism for this is unknown, one potential explanation may be that a small amount of GSK2256294 is distributed to a deep compartment and was then eliminated slowly.

GSK2256294 was well tolerated following both single and repeat dosing, and the majority of adverse events were classified as mild to moderate. Transient elevations of creatinine were noted in the single dose cohorts of the FTIH study that were considered possibly drug-related, and occurred primarily in subjects receiving GSK2256294. These events were only noted at a single time point, occurred soon after a meal and only at 2 and 6 mg but not higher doses, and did not re-occur with subsequent dosing, nor were they associated with elevations in serum cystatin C or urinalysis abnormalities. No changes in creatinine were observed in the repeat dose cohorts. The etiology of these transient changes is unknown. One possibility which

may explain why this was only seen at lower doses, and not in repeat dosing, is the fact that the 12 hour blood sampling point was only done in Cohorts 1 and 2, i.e. immediately after the evening meal, and that the changes in creatinine were related to dietary intake (a heavy protein meal eaten immediately prior to sampling) as previously reported in the literature [30], although a formal dietary chart was not kept for the trial.

In pre-clinical models, EETs increase the proliferation and survival of endothelial cells [31] as well as induce angiogenesis [32,33]. The critical role for EETs in organ regeneration and tissue repair may be dependent on this effect [34]. Using the same experimental model, investigators also demonstrated that transgenic overexpression of EETs or inhibition of sEH promoted tumor growth and metastasis [35]. In contrast, dual inhibition of cyclo-oxygenase 2 and soluble epoxide hydrolase has demonstrated synergistic anti-angiogenic and anti-cancer activity [36]. The relevance of these models to humans is unknown, but suggests that the regulation of sEH activity and tissue EETs in tumor growth is complex. In the FTIH study, serum VEGF concentrations were not increased following 2 weeks of dosing with GSK2256294, and actually trended lower in subjects who received the higher dose. One might speculate that in presence of an sEH inhibitor, stabilization of EET levels results in enhanced local utilization reducing concentrations of VEGF, although long term studies are necessary to fully assess the potential effects.

More recent studies have suggested that under conditions of low VEGF signaling, EETs may increase the response to VEGF [23,24], thus, offering a novel therapeutic approach to target endothelial apoptosis and subsequent tissue loss, as has been demonstrated in emphysema [37–41]. Our results demonstrate that sEH inhibition with GSK2256294 is well tolerated, with rapid and sustained target inhibition. The results from these studies provide a meaningful rationale for future studies with

GSK2256294, particularly in diseases characterized by endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or emphysema.

British Journal of Clinical Pharmacology

Acknowledgements

The authors would like to thank the study volunteers, Dr. Disala Fernando and the staff at the GSK Clinical Unit Cambridge, Addenbrooke's Centre for Clinical Investigation (UK) and at the Parexel Early Phase Clinical Unit (Baltimore, MD, USA), and Wayne Wright (GSK) for sEH enzyme assay and leukotoxin biomarker methodology development. LY is funded by a Wellcome Trust-GSK Translational Medicine and Therapeutics (TMAT) Studentship and a Raymond and Beverley Sackler Fellowship. IW is a British Heart Foundation Senior Clinical Fellow, and both JC and IW are supported by the Cambridge NIHR Biomedical Research Centre.

Competing Interests

AL, JR, NG, RB, SB, RTS and RM are GSK employees and shareholders. JC is employed by Cambridge University Hospitals NHS Foundation Trust and is obligated to spend 50% of his time on GSK clinical trial research; however, he receives no other benefits or compensation from GSK. DN has received consultancy fees from GSK; IW has received educational grants from GSK. LY has no conflicts to declare.

Funding for the two studies (NCT01762774 and NCT02006537) was provided by GSK. Partial funding for Study 1 was provided by the Innovate UK Stratified Medicines programme (ERICA Consortium).

Contributions

AL, JR, NG, RB, RM, DN, IW and JC designed the clinical studies; SB developed the assay methodology; all authors analyzed and/or interpreted the data; AL and LY wrote the first draft; all authors reviewed and approved the manuscript.

Figure Legends

Figure 1: Subject Disposition, Study 1

Figure 2: Single and Repeat Dose Pharmacokinetics of GSK2256294.

Concentration-time plots following single (A) and repeat (B) doses of GSK2256294. Data are expressed as mean \pm SD. HV-healthy volunteer; OS-overweight smoker

Figure 3: Dose-dependent inhibition of sEH enzyme activity. Percent inhibition of sEH enzyme activity following single (A) and repeat (B) dosing with GSK2256294. Data are expressed as mean \pm SD. HV-healthy volunteer; OS-overweight smoker

References

1. Morisseau C, Hammock BD. Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health. *Annual Review of Pharmacology and Toxicology*. 2012. p. 37–58.
2. Zhang G, Kodani S, Hammock BD. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. *Prog Lipid Res*. 2014;53(1):108–23.
3. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. *Am J Physiol Cell Physiol*. 2007;292(3):C996–1012.
4. Bellien J, Joannides R, Richard V, Thuillez C. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: A promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? *Pharmacol Ther*. 2011;131(1):1–17.
5. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nat Rev Drug Discov*. 2009;8(10):794–805.
6. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. *Science*. 1999;285(5431):1276–9.
7. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. *J Pharmacol Exp Ther*. 2003;307(2):753–64.
8. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, Lee, C, Zeldin DC, Schwartzman ML. CYP2J2 targeting to endothelial cells attenuates adiposity and Vascular Dysfunction in Mice Fed a High-Fat Diet by Reprogramming Adipocyte Phenotype. *Hypertension*. 2014;64(6):1352–61.
9. Dufлот T, Roche C, Lamoureux F, Guerrot D, Bellien J. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. *Expert Opin Drug Discov*. 2014;9(3):229–43.
10. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: The road to translation. *Journal of Molecular and Cellular Cardiology*. 2014. p. 199–208.
11. Zheng J, Plopper CG, Lakritz J, Storms DH, Hammock BD. Leukotoxin-diol: A putative toxic mediator involved in acute respiratory distress syndrome. *Am J Respir Cell Mol Biol*. 2001;25(4):434–8.
12. Yang J, Bratt J, Franzi L, Liu J-Y, Zhang G, Zeki A, Voge CF, Williams K, Dong H, Lin Y, Hwang SH, Kenyon NJ, Hammock BD. Soluble Epoxide Hydrolase Inhibitor Attenuates Inflammation and Airway Hyperresponsiveness in Mice. *Am J Respir Cell Mol Biol*. 2015;52(1):46–55.

13. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock BD, Pinkerton, Kent E.. Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol*. 2012;46(5):614–22.
14. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. *Proc Natl Acad Sci U S A*. 2005;102(6):2186–91.
15. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S, Chalfant C, Conrad DH, Kepley CL. Epoxyeicosatrienoic acids are involved in the C 70 fullerene derivative-induced control of allergic asthma. *J Allergy Clin Immunol*. 2012;130(3).
16. Zhou Y, Sun G-Y, Liu T, Duan J-X, Zhou H-F, Lee KS, Hammock BD, Fang X, Jiang J-X, Guan C-X. Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice. *Cell Tissue Res*. 2015;. Available from: <http://link.springer.com/10.1007/s00441-015-2262-0>
17. Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, Douda DH, Tabet Y, Khaddaj-Mallat R, Sirois M, Sirois C, Rizcallah E, Rousseau E, Martin R, Sutherland ER, Castro M, Jarjour N, Israel E, Levy BD.. Lipoxin Generation Is Related to Soluble Epoxide Hydrolase Activity in Severe Asthma. *Am J Respir Crit Care Med* . 2014;190(8):886–97.
18. Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do, Zung N, Mehra U, Tran V. 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. *Bioorganic Med Chem Lett*. 2011;21(3):983–8.
19. Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV, Anandan SK, Gless R, Webb HK. Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects. *The Journal of Clinical Pharmacology*. 2012. p. 319–28.
20. Podolin PL, Bolognese BJ, Foley JF, Long E, Peck B, Umbrecht S, Zhang X, Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M, Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP, Kurali E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. *Prostaglandins Other Lipid Mediat [Internet]*. 2013;104-105:25–31.
21. Lazaar AL, Yang L, Robertson J, Goyal N, Boardley R, Tal-Singer R, Cheriyan J, Newby D, Wilkinson I, Mayer RJ. Safety and pharmacology of a soluble epoxide hydrolase inhibitor. *European Respiratory Society*. 2015. Available from: <http://erscongress.org/key4.html>
22. Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney WJ. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. *Br J Clin Pharmacol*. 2013;75(2):488–96.

23. Webler AC, Michaelis UR, Popp R, Barbosa-Sicard E, Murugan A, Falck JR, Fisslthaler B, Fleming I. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. *Am J Physiol Cell Physiol.* 2008;295(5):C1292–301.
24. Yang S, Wei S, Pozzi A, Capdevila JH. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. *Arch Biochem Biophys.* 2009;489(1-2):82–91.
25. Keserü B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD, Weissmann N, Fisslthaler B, Fleming I. Hypoxia-induced pulmonary hypertension: Comparison of soluble epoxide hydrolase deletion vs. inhibition. *Cardiovasc Res.* 2010;85(1):232–40.
26. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. *Nat Med.* 1997;3(5):562–6.
27. Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer J-L. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. *Br J Clin Pharmacol.* 2004;58(6):618–31.
28. Zhao X, Dey A, Romanko OP, Stepp DW, Wang M-H, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. *Am J Physiol Regul Integr Comp Physiol.* 2005;288(1):R188–96.
29. Wei Q, Doris PA, Pollizotto M V., Boerwinkle E, Jacobs DR, Siscovick DS, Fornage M. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: Interaction with cigarette smoking. *Atherosclerosis.* 2007;190(1):26–34.
30. Jacobsen FK, Christensen CK, Mogensen CE, Andreassen F, Heilskov NS. Postprandial serum creatinine increase in normal subjects after eating cooked meat. *Proc Eur Dial Transplant Assoc.* 1979;16:506–12.
31. Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck JR, Harder DR, Jacobs ER, Pratt PF. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. *Prostaglandins and Other Lipid Mediators.* 2007. 1-4:19–29.
32. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. *J Biol Chem.* 2005;280(29):27138–46.
33. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. *Prostaglandins and Other Lipid Mediators.* 2007. p. 60–7.
34. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, Lee CR, Benny O, Mudge DK, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson MA, Akino T, Lih FB, Tomer KB, Ingber DE,

- Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC, Kieran MW. Epoxyeicosanoids promote organ and tissue regeneration. *Proc Natl Acad Sci U S A*. 2013;110(33):13528–33.
35. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio J, Pietramaggiore G, Scherer-Pietramaggiore SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. *J Clin Invest*. 2012;122(1):178–91.
36. Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu J-Y, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. *Proc Natl Acad Sci*. 2014;111(30):11127–32.
37. Janssen WJ, Yunt ZX, Muldrow A, Kearns MT, Kloepfer A, Barthel L, Bratton DL, Bowler RP, Henson PM. Circulating hematopoietic progenitor cells are decreased in COPD. *COPD*. 2014;11(3):277–89.
38. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. *Journal of Clinical Investigation*. 2008. p. 394–402.
39. Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, Zhang, Z I. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. *Cytotherapy*. 2010;12(5):605–14.
40. Tang K, Rossiter HB, Wagner PD, Breen EC. Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. *J Appl Physiol*. 2004;97(4):1559–66.
41. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. *J Clin Invest*. 2000;106(11):1311–9.

Table 1: Selected Plasma GSK2256294 Pharmacokinetic Parameters

| Treatment | C _{max} (ng/mL) | AUC(0-24) (ng.h/mL) | AUC(0-∞) (ng.h/mL) | t _{1/2} (h) | t _{max} (h) |
|-----------------|-----------------------------|------------------------|-----------------------|-------------------------|-------------------------|
| Cohort 1 (SD) | | | | | |
| 2mg | 29.6 (79.6) | 111 (124) | 1272 (17.9) | 29.9 (11.8) | 0.50 (0.3-1.0) |
| 6mg | 321 (44.7) | 2471 (37.3) | 3376 (37.3) | 25.0 (23.6) | 1.00 (0.5-4.0) |
| 12mg | 836 (33.4) | 6680 (23.4) | 8641 (26.8) | 19.3 (11.0) | 0.63 (0.5-1.0) |
| Cohort 2 (SD) | | | | | |
| 6mg | 333 (29.4) | 3244 (18.4) | 5905 (24.7) | 48.8 (36.3) | 1.00 (0.5-3.0) |
| 10mg | 559 (32.8) | 5267 (34.6) | 9611 (46.9) | 42.7 (52.7) | 1.00 (0.5-2.0) |
| 20mg | 1223 (23.2) | 11464 (31.0) | 17359 (35.8) | 41.4 (35.7) | 1.00 (0.5-4.0) |
| Cohort 3-4 (RD) | | | | | |
| 6mg | 689 (33.2) | 5801 (57.5) | ND | ND | 0.52 (0.5-1.0) |
| 18mg | 1455 (29.1) | 15774 (36.3) | ND | ND | 0.50 (0.5-2.0) |

Selected pharmacokinetic parameters from the FTIH study (Study 1), expressed as geometric mean (coefficient of variance [CV]%), with the exception of t_{max}, which is expressed as median (range). ND-not determined; SD-single dose; RD-14 day repeat dose




Figure 1
163x83mm (96 x 96 DPI)




Figure 2: Single and Repeat Dose Pharmacokinetics of GSK2256294. Concentration-time plots following single (A) and repeat (B) doses of GSK2256294. Data are expressed as mean \pm SD. HV-healthy volunteer; OS-overweight smoker
222x105mm (96 x 96 DPI)




Figure 3: Dose-dependent inhibition of sEH enzyme activity. Percent inhibition of sEH enzyme activity following single (A) and repeat (B) dosing with GSK2256294. Data are expressed as mean \pm SD. HV-healthy volunteer; OS-overweight smoker
222x100mm (96 x 96 DPI)

Supplemental Data

Leukotoxin/Leukotoxin-diol (LT/LTD) Assays

Blood samples were collected from subjects in Cohorts 3-4, into EDTA containing tubes, placed on crushed ice prior to centrifugation to obtain plasma (ca. 1500 x g for 15 minutes, 4°C) and stored at -20°C or colder (within 1h of blood collection). Samples were analysed for the determination of endogenous levels of LT converted to LTD by LC/MS/MS, with assay LLQs of 250 pg/mL and 50 pg/mL, respectively.

Table S1: Demography

Study 1

| Demographics | Single Dose | | Repeat Dose | | |
|---|--------------------|--------------------|---------------------------|----------------------------|------------------|
| | Cohort 1 (n=14) | Cohort 2 (n=13) | GSK2256294 6 mg (n=11) | GSK2256294 18 mg (n=12) | Placebo (n=6) |
| Age in Years Mean (SD) | 32.4 (7.92) | 38.9 (9.57) | 42.9 (10.48) | 42.4 (9.46) | 41.3 (8.04) |
| Sex [n (%)] | | | | | |
| Male: | 14 (100) | 13 (100) | 11 (100) | 12 (100) | 6 (100) |
| BMI (kg/m ²) Mean (SD) | 23.15 (1.446) | 30.26 (1.640) | 30.55 (1.675) | 30.92 (2.265) | 30.55 (2.894) |
| Height (cm) Mean (SD) | 178 (5.0) | 181 (4.7) | 183 (6.0) | 178 (4.3) | 176 (9.0) |
| Weight (kg) Mean (SD) | 73.2 (6.57) | 98.9 (8.80) | 102.8 (9.90) | 98.3 (10.14) | 94.5 (9.24) |
| Ethnicity n (%) | | | | | |
| Not Hispanic or Latino: | 14 (100) | 13 (100) | 11 (100) | 12 (100) | 6 (100) |
| Race n (%) | | | | | |
| Asian – South East Asian Heritage | 0 | 1 (8) | 1 (9) | 1 (8) | 0 |
| Black or African American | 1 (7) | 0 | 0 | 2 (17) | 0 |
| White – White/Caucasian/European Heritage | 13 (93) | 12 (92) | 10 (91) | 9 (75) | 6 (100) |

Study 2

| Demographics | Cohort 1 (N=8) | Cohort 2 (N=18) |
|---|---------------------|---------------------|
| Age in Years [Median (Range)] | 36 (20-40) | 62 (59-75) |
| Sex [n (%)] | | |
| Female: | 0 | 8 (44) |
| Male: | 8 (100) | 10 (56) |
| BMI (kg/m ²) [Median (Range)] | 24.50 (20.40-28.80) | 27.85 (21.50-33.00) |
| Height (m) [Median (Range)] | 1.77 (1.66-1.90) | 1.73 (1.58-1.91) |
| Weight (kg) [Median (Range)] | 79.3 (61.2-100.0) | 79.3 (64.2-113.0) |
| Ethnicity [n (%)] | | |
| Hispanic or Latino: | 2 (25) | 1 (6) |
| Not Hispanic or Latino: | 6 (75) | 17 (94) |
| Race [n (%)] | | |
| African American/African Heritage | 5 (63) | 11 (61) |
| Asian – South East Asian Heritage | 0 | 1 (6) |
| White – White/Caucasian/European Heritage | 3 (38) | 6 (33) |

Supplemental Table 2: Adverse Events reported in Cohort 1, study 1

| System organ class preferred term, n (%) | Placebo (n=12) | GSK2256294 2 mg (n=12) | GSK2256294 6 mg (n=12) | GSK2256294 12 mg (n=12) |
|---|----------------|------------------------|------------------------|-------------------------|
| Subjects with Any Adverse Event | 4 (33) | 9 (75) | 8 (67) | 6 (50) |
| Skin and subcutaneous tissue disorders | | | | |
| Dermatitis contact | 0 | 4 (33) | 3 (25) | 1 (8) |
| Nervous system disorders | | | | |
| Headache | 2 (17) | 1 (8) | 2 (17) | 3 (25) |
| General disorders and administration site conditions | | | | |
| Catheter site erythema | 0 | 0 | 0 | 2 (17) |
| Investigations | | | | |
| Blood creatinine increased | 0 | 2 (17) | 1 (8) | 0 |

Supplemental Table 3: Adverse Events reported in Cohort 2, study 1

| System organ class preferred term, n (%) | Placebo (n=12) | GSK2256294 2 mg (n=12) | GSK2256294 6 mg (n=12) | GSK2256294 12 mg (n=12) |
|---|----------------|------------------------|------------------------|-------------------------|
| Subjects with Any Adverse Event | 7 (64) | 7 (64) | 8 (80) | 6 (75) |
| Nervous system disorders | | | | |
| Headache | 3 (27) | 2 (18) | 3 (30) | 2 (25) |
| Somnolence | 0 | 0 | 0 | 2 (25) |
| Musculoskeletal and connective tissue disorders | | | | |
| Back pain | 0 | 2 (18) | 0 | 1 (13) |
| Gastrointestinal disorders | | | | |
| Flatulence | 0 | 1 (9) | 2 (20) | 0 |
| General disorders and administration site conditions | | | | |
| Fatigue | 3 (27) | 0 | 1 (10) | 0 |
| Infections and infestations | | | | |
| Nasopharyngitis | 0 | 2 (18) | 0 | 0 |
| Investigations | | | | |
| Hepatic enzyme increased | 0 | 2 (18) | 0 | 0 |

Supplemental Table 4: Adverse Events reported in Cohorts 3 and 4, Study 1

| System organ class preferred term, n (%) | Placebo (n=6) | GSK2256294 6 mg (n=11) | GSK2256294 18 mg (n=12) |
|--|---------------|------------------------|-------------------------|
| Subjects with Any Adverse Event | 5 (83) | 9 (82) | 9 (75) |
| Nervous system disorders | | | |
| Headache | 3 (50) | 4 (36) | 5 (42) |
| Dizziness | 0 | 0 | 2 (17) |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | 1 (17) | 2 (18) | 0 |
| Neck pain | 0 | 1 (9) | 2 (17) |
| Gastrointestinal disorders | | | |
| Abdominal pain | 0 | 2 (18) | 0 |
| Infections and infestations | | | |
| Nasopharyngitis | 0 | 3 (27) | 2 (17) |

Supplemental Table S5: Adverse events reported in Study 2

| System Organ Class Preferred Term | GSK2256294 10 mg (N=8) | GSK2256294 10 mg (N=18) |
|---|------------------------|-------------------------|
| Subjects with Any Adverse Event | 2 (25) | 1 (6) |
| Gastrointestinal disorders | | |
| Flatulence | 0 | 1 (6) |
| General disorders and administration site conditions | | |
| Catheter site swelling | 1 (13) | 0 |
| Musculoskeletal and connective tissue disorders | | |
| Pain in extremity | 1 (13) | 0 |